Level D· Scientific groundwork from lab and animal studiesAnimal StudyEurope PMCOpen access

Optimal timing of bone marrow aspiration concentrate injection for tendon-bone healing in a chronic rat rotator cuff tear model

Wang C., Zeng H., Shi Q., Jiang H.

Animal Study on Cartilage Damage, Tendon Injury, Rotator Cuff, Chronic Wound, published in J Orthop Surg Res (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
J Orthop Surg Res (2025)
Reported sample size
—
Source database
Europe PMC
PMID
40993702
PMCID
PMC12462254
DOI
10.1186/s13018-025-06253-6

Abstract (original English)

Background The Bone marrow aspirate concentrate (BMAC) injection is a beneficial therapy for bone-tendon interface (BTI) regeneration following rotator cuff (RC) repair. However, the optimal timing for BMAC injection remains undetermined. Injection at different timepoints may influence BTI regeneration. Methods After concentrating bone marrow (BM) to obtain BMAC, the viability of cells, nucleated cell content, platelet count, stem cell number, and concentration of growth factors in both BM and BMAC were comparatively evaluated. Supraspinatus tendon tears were induced at the greater tuberosity in 152 Wistar rats. Three weeks after the tear induction, the rats following RC repair surgery were then randomly divided into four groups based on the timing of BMAC injection: PBS injected immediately during RC repair (PBS group), BMAC injected immediately (P0-BMAC group), on postoperative day 7 (P7-BMAC group), or day 14 (P14-BMAC group). Eight weeks after RC repair, the supraspinatus tendon-proximal humerus complexes were harvested for evaluating BTI regeneration using micro-CT, histological and biomechanical testing. Additionally, at the day 0, 3, 10, 17 after RC repair, the specimens were harvested for evaluating the inflammation and oxidative stress. Results Cell viability in the BMAC exceeded 90%. The BMAC contained higher concentrations of platelets, nucleated cells, stem cells, T

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Rotator CuffAnimalsRatsRats, WistarDisease Models, AnimalChronic DiseaseBone Marrow TransplantationWound HealingTime FactorsMale

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research